| Literature DB >> 10499158 |
S Schenker1, Y Yang, E Mattiuz, D Tatum, M Lee.
Abstract
1. The present study assessed the human transplacental transport of olanzapine, a new antipsychotic drug effective in the treatment of schizophrenia. 2. Using the normal-term placenta perfused single cotyledon system, we show that: (i) 5-14% of labelled olanzapine crosses from the maternal to foetal compartments in 4 h; (ii) transport depends significantly on binding characteristics, especially of albumin; (iii) no oxidative metabolites of olanzapine appear in the placental perfusate over 4 h; and (iv) approximately 17% of olanzapine, on average, is converted to the glucuronide, which is transferred by the placenta at a rate slightly slower than the parent drug.Entities:
Mesh:
Substances:
Year: 1999 PMID: 10499158 DOI: 10.1046/j.1440-1681.1999.03111.x
Source DB: PubMed Journal: Clin Exp Pharmacol Physiol ISSN: 0305-1870 Impact factor: 2.557